– Our Platform
An innovative, targeted approach to treating cancer
Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation
FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More
Bexion Pharmaceuticals, Inc. to Present Clinical and Pre-Clinical Data at 2020 SNO Annual Meeting
FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More